Clinical Trial Update: Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a recombinant norovirus bivalent vaccine (GI.1/GII.4) produced in Hansenula polymorpha for Norovirus infections and Norwalk ga…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Norovirus Infections
• Norwalk Gastroenteritis

Drugs mentioned

• Norovirus bivalent vaccine (GI.1/GII.4) recombinant

Snippet

Sponsor: National Vaccine and Serum Institute, China | Conditions: Norovirus Infections, Norwalk Gastroenteritis | Phase 2 | Status: UNKNOWN